- supporting the Insulin Safety Week campaign to help reduce insulin errors
- protecting healthcare professionals from needlestick injuries
- helping ensure patients receive an accurate dose
- available from Owen Mumford, via Bunzl Healthcare and listed on the Drug Tariff
Its launch supports Insulin Safety Week’s campaign to lower insulin errors and comes after an independent survey* of over 100 HCPs that highlighted the risk of NSIs and the challenges of ensuring the correct dose is delivered.
With 3.8 million people in the UK living with Diabetes, and an estimated 20-30% of them treated with insulin, Trend Diabetes reports that insulin mistakes are common and may cause harm to the patient or, in severe cases, even death. The Insulin Trend report points out that insulin errors happened for 40% of all people with Type 1 Diabetes and 37% of all people with Type 2 Diabetes, showing how vital correct dosing really is.
Now that it’s listed on the Drug Tariff after NHS Prescription Services approval, GP Practices can prescribe the device and pharmacists can provide it to eligible patients. UnifineSafeControl is also now listed with Bunzl Healthcare, making it easier for NHS Trusts and other Primary Care providers to access it.
Daniel Hampson, Strategic Buyer at Bunzl Healthcare, says that in today’s healthcare environment the NHS and other organizations need to provide effective, cost-efficient patient care: “Bunzl Healthcare delivers a reliable, modern, and evolving supply chain service to drive efficiency on every level. We’re excited to also offer UnifineSafeControl to our customers.”
Joanne Thompson, General Manager, UK/Ireland and ROW at Owen Mumford, shares that the company is proud of the intelligent design of its safety pen needle: “This device reduces the risk of needlestick injuries, helping protect HCPs and patients from blood-borne viruses and infections,” she explains. “It’s designed to support accurate dosing, which could help save patients’ lives too.”
Leanne Adam, Marketing Manager at Owen Mumford, says Owen Mumford is dedicated to meeting HCP and patient needs by driving medical device innovation: “We’ve commissioned research and taken the time to understand HCP experiences and daily challenges, and how these impact patients’ lives. That’s helped us develop a solution designed with both HCPs and patients in mind.”
In their research*, around 92% of respondents said they were 100% sure the full medication dose was delivered using the new device, and 75% said it gave them the right safety and control during the injection process. Almost three quarters said they would rather use UnifineSafeControl when given the choice.
“The ability to control the injection process means HCPs and patients can have peace of mind that the full dose is being delivered. This is especially important for people living with Diabetes, since getting too much or too little insulin can be very dangerous and even life-threatening.”
- A recyclable green cap keeps the needle sterile and protected before injection
- Works with all major injection pen brands
- With UnifineSafeControl, HCPs use a familiar injection technique like conventional pen needles.
Leanne concludes: “While we supply directly to hospital trusts, we’re glad to give our customers more options by expanding distribution through Bunzl Healthcare. We truly believe UnifineSafeControl will meet the challenges HCPs face with passive safety pen needles, giving them confidence they’re providing the best care for patients while staying protected from NSIs.”